BACKGROUND/AIMS: Lanthanum carbonate (LC, FOSRENOL) is an effective phosphate binder for which tolerability and a safety profile have been reported in haemodialysis patients. Patients from previous studies entered a 2-year extension, enabling assessment of efficacy and safety for up to 6 years of LC monotherapy. METHODS: Patients from four previous trials entered this study. RESULTS: Ninety-three patients started the extension, with 22 entering a sixth year of LC treatment. Two-thirds of all patients received LC doses of 2,250 or 3,000 mg/day. Reductions in serum phosphate and calcium x phosphate product were maintained for up to 6 years. There were no new or unexpected adverse events (AEs), and no increase in the incidence of events with increasing treatment exposure. Over the complete duration of therapy, treatment-related AEs occurred in 25.8% of patients and were primarily gastrointestinal in nature. No clinically relevant changes in liver function tests were observed and there was no evidence of adverse effects on the liver, bone or the central nervous system. CONCLUSIONS: LC monotherapy was effective and well tolerated for up to 6 years with no evidence of safety concerns or increased frequency of AEs. Copyright 2008 S. Karger AG, Basel.
BACKGROUND/AIMS: Lanthanum carbonate (LC, FOSRENOL) is an effective phosphate binder for which tolerability and a safety profile have been reported in haemodialysis patients. Patients from previous studies entered a 2-year extension, enabling assessment of efficacy and safety for up to 6 years of LC monotherapy. METHODS:Patients from four previous trials entered this study. RESULTS: Ninety-three patients started the extension, with 22 entering a sixth year of LC treatment. Two-thirds of all patients received LC doses of 2,250 or 3,000 mg/day. Reductions in serum phosphate and calcium x phosphate product were maintained for up to 6 years. There were no new or unexpected adverse events (AEs), and no increase in the incidence of events with increasing treatment exposure. Over the complete duration of therapy, treatment-related AEs occurred in 25.8% of patients and were primarily gastrointestinal in nature. No clinically relevant changes in liver function tests were observed and there was no evidence of adverse effects on the liver, bone or the central nervous system. CONCLUSIONS:LC monotherapy was effective and well tolerated for up to 6 years with no evidence of safety concerns or increased frequency of AEs. Copyright 2008 S. Karger AG, Basel.
Authors: A J Hutchison; B Maes; J Vanwalleghem; G Asmus; E Mohamed; R Schmieder; W Backs; R Jamar; A Vosskuhler Journal: Nephron Clin Pract Date: 2005-04-04
Authors: Geert J Behets; Steven C Verberckmoes; Line Oste; An R Bervoets; Murielle Salomé; Alan G Cox; John Denton; Marc E De Broe; Patrick C D'Haese Journal: Kidney Int Date: 2005-05 Impact factor: 10.612
Authors: Bernard Lacour; Anthony Lucas; Daniel Auchère; Nadya Ruellan; Natalie Mariaud de Serre Patey; Tilman B Drüeke Journal: Kidney Int Date: 2005-03 Impact factor: 10.612
Authors: Patrick C D'Haese; Goce B Spasovski; Aleksander Sikole; Alastair Hutchison; Tony J Freemont; Sylvie Sulkova; Charles Swanepoel; Svetlana Pejanovic; Llubica Djukanovic; Alessandro Balducci; Giorgio Coen; Waldysaw Sulowicz; Anibal Ferreira; Armando Torres; Slobodan Curic; Milan Popovic; Nada Dimkovic; Marc E De Broe Journal: Kidney Int Suppl Date: 2003-06 Impact factor: 10.545
Authors: Geert J Behets; Geert Dams; Sven R Vercauteren; Stephen J Damment; Roger Bouillon; Marc E De Broe; Patrick C D'Haese Journal: J Am Soc Nephrol Date: 2004-08 Impact factor: 10.121
Authors: Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol Journal: Pediatr Nephrol Date: 2010-02-12 Impact factor: 3.714
Authors: Stuart M Sprague; Hanna Abboud; Ping Qiu; Matthew Dauphin; Pinggao Zhang; William Finn Journal: Clin J Am Soc Nephrol Date: 2008-12-03 Impact factor: 8.237
Authors: David Pierce; Stuart Hossack; Lynne Poole; Antoine Robinson; Heather Van Heusen; Patrick Martin; Michael Smyth Journal: Nephrol Dial Transplant Date: 2010-10-04 Impact factor: 5.992